文献速递重症综合管理与镇静镇痛儿科与产科急症

苯二氮䓬类药物与危重患儿谵妄发生:估计因果效应

Benzodiazepines and Development of Delirium in Critically Ill Children: Estimating the Causal Effect.
PubMed 文献 · Crit Care Med · 2018-01-01
一句话结论在危重患儿中,苯二氮䓬类药物暴露是谵妄发生的独立可干预危险因素,且存在剂量-反应关系,作者支持限制其使用。

该回顾性观察研究纳入2015年1月至6月连续收入学术三级PICU的全部患儿,住院期间用Cornell Assessment for Pediatric Delirium前瞻性筛查谵妄,每日认知状态分为谵妄、昏迷或正常。多变量混合效应模型显示苯二氮䓬类与从正常认知状态转为谵妄强相关,使谵妄发生率增加四倍以上(OR 4.4,95%CI 1.7-11.1,P<0.002);边际结构模型控制认知状态、机械通气和阿片类等时间依赖性混杂后,OR为3.3(95%CI 1.4-7.8)。苯二氮䓬类剂量每增加1个对数单位,谵妄发生风险增加43%。作者认为该时间关系提示苯二氮䓬暴露与儿童谵妄之间存在因果关联,并支持限制危重患儿使用苯二氮䓬类药物。

要点

  • 在危重患儿中,苯二氮䓬类暴露与从正常认知状态转为谵妄强相关,谵妄发生率增加四倍以上(OR 4.4,95%CI 1.7-11.1,P<0.002)。
  • 边际结构模型控制认知状态、机械通气和阿片类等时间依赖性混杂后,苯二氮䓬类与次日谵妄的OR为3.3(95%CI 1.4-7.8)。
  • 苯二氮䓬类剂量每增加1个对数单位,谵妄发生风险增加43%,存在剂量-反应关系。
  • 作者认为该时间关系提示苯二氮䓬暴露与儿童谵妄之间存在因果关联,并支持限制危重患儿使用苯二氮䓬类药物。

适用人群与场景

  • 2015年1月至6月连续收入学术三级PICU的全部患儿,住院期间前瞻性筛查谵妄。

诊断标准与关键阈值

  • 使用Cornell Assessment for Pediatric Delirium全程前瞻性筛查谵妄,每日认知状态分为谵妄、昏迷或正常。

研究设计与关键结果

  • 回顾性观察研究,纳入2015年1月至6月连续收入学术三级PICU的全部患儿,住院期间用Cornell Assessment for Pediatric Delirium前瞻性筛查谵妄。
  • 多变量混合效应模型显示苯二氮䓬类与从正常认知状态转为谵妄强相关,使谵妄发生率增加四倍以上(OR 4.4,95%CI 1.7-11.1,P<0.002)。
  • 边际结构模型控制认知状态、机械通气和阿片类等时间依赖性混杂后,苯二氮䓬类与次日谵妄的OR为3.3(95%CI 1.4-7.8)。
  • 苯二氮䓬类剂量每增加1个对数单位,谵妄发生风险增加43%。

证据类型、等级与局限

  • 证据类型:回顾性观察研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为该时间关系提示苯二氮䓬暴露与儿童谵妄之间存在因果关联,并支持限制危重患儿使用苯二氮䓬类药物。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVES: Benzodiazepine use may be associated with delirium in critically ill children. However, benzodiazepines remain the first-line sedative choice in PICUs. Objectives were to determine the temporal relationship between administration of benzodiazepines and delirium development, control for time-varying covariates such as mechanical ventilation and opiates, and evaluate the association between dosage of benzodiazepines and subsequent delirium.

DESIGN: Retrospective observational study.

SETTING: Academic tertiary care PICU.

PATIENTS: All consecutive admissions from January 2015 to June 2015.

INTERVENTIONS: Retrospective assessment of benzodiazepine exposure in a population that had been prospectively screened for delirium.

MEASUREMENTS AND MAIN RESULTS: All subjects were prospectively screened for delirium throughout their stay, using the Cornell Assessment for Pediatric Delirium, with daily cognitive status assigned as follows: delirium, coma, or normal. Multivariable mixed effects modeling determined predictors of delirium overall, followed by subgroup analysis to assess effect of benzodiazepines on subsequent development of delirium. Marginal structural modeling was used to create a pseudorandomized sample and control for time-dependent variables, obtaining an unbiased estimate of the relationship between benzodiazepines and next day delirium. The cumulative daily dosage of benzodiazepines was calculated to test for a dose-response relationship. Benzodiazepines were strongly associated with transition from normal cognitive status to delirium, more than quadrupling delirium rates (odds ratio, 4.4; CI, 1.7-11.1; p < 0.002). Marginal structural modeling demonstrated odds ratio 3.3 (CI, 1.4-7.8), after controlling for time-dependent confounding of cognitive status, mechanical ventilation, and opiates. With every one log increase in benzodiazepine dosage administered, there was a 43% increase in risk for delirium development.

CONCLUSIONS: Benzodiazepines are an independent and modifiable risk factor for development of delirium in critically ill children, even after carefully controlling for time-dependent covariates, with a dose-response effect. This temporal relationship suggests causality between benzodiazepine exposure and pediatric delirium and supports limiting the use of benzodiazepines in critically ill children.

来源:Crit Care Med,查看原文。版权归原作者所有。

参考来源

  1. Mody K, Kaur S, Mauer EA, et al. Benzodiazepines and Development of Delirium in Critically Ill Children: Estimating the Causal Effect. Crit Care Med. 2018. PMID: 29727363. doi:10.1097/CCM.0000000000003194

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。